SRC-3 Inhibition Blocks Tumor Growth of Pancreatic Ductal Adenocarcinoma

Overview

Journal Cancer Lett

Specialty Oncology

Date 2018 Nov 14

PMID 30423406

Citations 12

Authors

Xianzhou Song

Hui Chen

Chengwei Zhang

Yang Yu

Zhongyuan Chen

Han Liang

George Van Buren 2nd

Amy L McElhany

William E Fisher

David M Lonard

Bert W OMalley

Jin Wang

Affiliations

Soon will be listed here.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant and lethal disease with few treatment options. Steroid receptor coactivator-3 (SRC-3, also known as NCOA3, AIB1, pCIP, ACTR, RAC3, TRAM1) sits at the nexus of many growth signaling pathways and has been pursued as a therapeutic target for breast, prostate and lung cancers. In this study, we find that SRC-3 is overexpressed in PDAC and inversely correlates with patient overall survival. Knockdown of SRC-3 reduces pancreatic cancer cell proliferation, migration and invasion in vitro. Additionally, inhibition of SRC-3 using either shRNA or a small molecule inhibitor can significantly inhibit tumor growth in orthotopic pancreatic cancer mouse models. Collectively, this study establishes SRC-3 as a promising therapeutic target for pancreatic cancer treatment.

Citing Articles

Integrative Analysis of scRNA-Seq and Bulk RNA-Seq Identifies Plasma Cell Related Genes and Constructs a Prognostic Model for Hepatocellular Carcinoma.

Tang M, Xu Y, Pan M J Hepatocell Carcinoma. 2025; 12:427-444.

PMID: 40040881 PMC: 11878290. DOI: 10.2147/JHC.S509749.

Lead Compound Development of SRC-3 Inhibitors with Improved Pharmacokinetic Properties and Anticancer Efficacy.

Lu D, Chen J, Qin L, Bijou I, Yi P, Li F J Med Chem. 2024; 67(7):5333-5350.

PMID: 38551814 PMC: 11105966. DOI: 10.1021/acs.jmedchem.3c01596.

Identification of a chromatin regulator signature and potential candidate drugs for bladder cancer.

Zhu K, Liu X, Deng W, Wang G, Fu B Hereditas. 2022; 159(1):13.

PMID: 35125116 PMC: 8819906. DOI: 10.1186/s41065-021-00212-x.

SRC-3, a Steroid Receptor Coactivator: Implication in Cancer.

Li L, Deng C, Chen Q Int J Mol Sci. 2021; 22(9).

PMID: 33946224 PMC: 8124743. DOI: 10.3390/ijms22094760.

The Biological Significance of Targeting Acetylation-Mediated Gene Regulation for Designing New Mechanistic Tools and Potential Therapeutics.

OGarro C, Igbineweka L, Ali Z, Mezei M, Mujtaba S Biomolecules. 2021; 11(3).

PMID: 33803759 PMC: 8003229. DOI: 10.3390/biom11030455.

References

Wang Y, Wu M, Sham J, Zhang W, Wu W, Guan X . Prognostic significance of c-myc and AIB1 amplification in hepatocellular carcinoma. A broad survey using high-throughput tissue microarray. Cancer. 2002; 95(11):2346-52. DOI: 10.1002/cncr.10963. View

Ryan D, Hong T, Bardeesy N . Pancreatic adenocarcinoma. N Engl J Med. 2014; 371(11):1039-49. DOI: 10.1056/NEJMra1404198. View

Song X, Zhang C, Zhao M, Chen H, Liu X, Chen J . Steroid Receptor Coactivator-3 (SRC-3/AIB1) as a Novel Therapeutic Target in Triple Negative Breast Cancer and Its Inhibition with a Phospho-Bufalin Prodrug. PLoS One. 2015; 10(10):e0140011. PMC: 4592245. DOI: 10.1371/journal.pone.0140011. View

Gao Z, Chiao P, Zhang X, Zhang X, Lazar M, Seto E . Coactivators and corepressors of NF-kappaB in IkappaB alpha gene promoter. J Biol Chem. 2005; 280(22):21091-8. PMC: 1237005. DOI: 10.1074/jbc.M500754200. View

Osborne C, Bardou V, Hopp T, Chamness G, Hilsenbeck S, Fuqua S . Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst. 2003; 95(5):353-61. DOI: 10.1093/jnci/95.5.353. View

Rohira A, Yan F, Wang L, Wang J, Zhou S, Lu A . Targeting SRC Coactivators Blocks the Tumor-Initiating Capacity of Cancer Stem-like Cells. Cancer Res. 2017; 77(16):4293-4304. PMC: 5559321. DOI: 10.1158/0008-5472.CAN-16-2982. View

Yan J, Erdem H, Li R, Cai Y, Ayala G, Ittmann M . Steroid receptor coactivator-3/AIB1 promotes cell migration and invasiveness through focal adhesion turnover and matrix metalloproteinase expression. Cancer Res. 2008; 68(13):5460-8. PMC: 2826835. DOI: 10.1158/0008-5472.CAN-08-0955. View

Kuang S, Liao L, Wang S, Medina D, OMalley B, Xu J . Mice lacking the amplified in breast cancer 1/steroid receptor coactivator-3 are resistant to chemical carcinogen-induced mammary tumorigenesis. Cancer Res. 2005; 65(17):7993-8002. DOI: 10.1158/0008-5472.CAN-05-1179. View

Jemal A, Siegel R, Xu J, Ward E . Cancer statistics, 2010. CA Cancer J Clin. 2010; 60(5):277-300. DOI: 10.3322/caac.20073. View

10.

Gregory C, He B, Johnson R, Ford O, Mohler J, French F . A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res. 2001; 61(11):4315-9. View

11.

Anzick S, Kononen J, Walker R, Azorsa D, TANNER M, Guan X . AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science. 1997; 277(5328):965-8. DOI: 10.1126/science.277.5328.965. View

12.

Samuel N, Hudson T . The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma. Nat Rev Gastroenterol Hepatol. 2011; 9(2):77-87. DOI: 10.1038/nrgastro.2011.215. View

13.

Gnanapragasam V, Leung H, Pulimood A, Neal D, Robson C . Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer. Br J Cancer. 2001; 85(12):1928-36. PMC: 2364015. DOI: 10.1054/bjoc.2001.2179. View

14.

Long W, Foulds C, Liu J, Ding C, Lonard D, Solis L . ERK3 signals through SRC-3 coactivator to promote human lung cancer cell invasion. J Clin Invest. 2012; 122(5):1869-80. PMC: 3336992. DOI: 10.1172/JCI61492. View

15.

Song X, Chen J, Zhao M, Zhang C, Yu Y, Lonard D . Development of potent small-molecule inhibitors to drug the undruggable steroid receptor coactivator-3. Proc Natl Acad Sci U S A. 2016; 113(18):4970-5. PMC: 4983835. DOI: 10.1073/pnas.1604274113. View

16.

Wang Y, Lonard D, Yu Y, Chow D, Palzkill T, Wang J . Bufalin is a potent small-molecule inhibitor of the steroid receptor coactivators SRC-3 and SRC-1. Cancer Res. 2014; 74(5):1506-1517. PMC: 3947477. DOI: 10.1158/0008-5472.CAN-13-2939. View

17.

Fleming F, Myers E, Kelly G, Crotty T, McDermott E, OHiggins N . Expression of SRC-1, AIB1, and PEA3 in HER2 mediated endocrine resistant breast cancer; a predictive role for SRC-1. J Clin Pathol. 2004; 57(10):1069-74. PMC: 1770462. DOI: 10.1136/jcp.2004.016733. View

18.

Hudelist G, Czerwenka K, Kubista E, Marton E, Pischinger K, Singer C . Expression of sex steroid receptors and their co-factors in normal and malignant breast tissue: AIB1 is a carcinoma-specific co-activator. Breast Cancer Res Treat. 2003; 78(2):193-204. DOI: 10.1023/a:1022930710850. View

19.

Long W, Yi P, Amazit L, Lamarca H, Ashcroft F, Kumar R . SRC-3Delta4 mediates the interaction of EGFR with FAK to promote cell migration. Mol Cell. 2010; 37(3):321-32. PMC: 2824333. DOI: 10.1016/j.molcel.2010.01.004. View

20.

Mo P, Zhou Q, Guan L, Wang Y, Wang W, Miao M . Amplified in breast cancer 1 promotes colorectal cancer progression through enhancing notch signaling. Oncogene. 2014; 34(30):3935-3945. PMC: 4377317. DOI: 10.1038/onc.2014.324. View